Lymphedema beyond breast cancer

Cancer

Volumn 116, Issue 22, 2010, Pages 5138-5149

  Cormier, Janice N ^a   Askew, Robert L ^a   Mungovan, Kristi S ^a   Xing, Yan ^a   Ross, Merrick I ^a   Armer, Jane M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

cancer; lymphedema; meta analysis; surgery; survivorship; systematic review

Indexed keywords

BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CLINICAL TRIAL; DISSECTION; FOLLOW UP; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LYMPHEDEMA; MELANOMA; META ANALYSIS; PELVIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SARCOMA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHEDEMA; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; QUALITY CONTROL; RISK FACTORS;

EID: 78449283134     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25458     Document Type: Review

References (73)

1. Rockson SG, Rivera KK., Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008; 1131: 147-154.
2. Norman SA, Localio AR, Potashnik SL, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009; 27: 390-397.
3. Morgan PA, Franks PJ, Moffatt CJ., Health-related quality of life with lymphoedema: a review of the literature. Int Wound J. 2005; 2: 47-62.
4. Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009; 27: 2007-2014.
5. Armer JM., The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest. 2005; 23: 76-83.
6. Petrek JA, Heelan MC., Incidence of breast carcinoma-related lymphedema. Cancer. 1998; 83 (12 suppl): 2776-2781.
7. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL., Arm edema in breast cancer patients. J Natl Cancer Inst. 2001; 93: 96-111.
8. McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008; 26: 5213-5219.
9. Borghouts JA, Koes BW, Bouter LM., The clinical course and prognostic factors of non-specific neck pain: a systematic review. Pain. 1998; 77: 1-13.
10. Kuijpers T, van der Windt DA, van der Heijden GJ, Bouter LM., Systematic review of prognostic cohort studies on shoulder disorders. Pain. 2004; 109: 420-431.
11. Scholten-Peeters GG, Verhagen AP, Bekkering GE, et al. Prognostic factors of whiplash-associated disorders: a systematic review of prospective cohort studies. Pain. 2003; 104: 303-322.
12. Mols F, Vingerhoets AJ, Coebergh JW, van de Poll-Franse LV., Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer. 2005; 41: 2613-2619.
13. Gelman A., Bayesian Data Analysis. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2004.
14. Spiegelhalter D, Thomas A, Best N., WINBUGS Version 1.4 User Manual: MRC Biostatistics Unit; 2003.
15. Gelman A, Rubin D., Inference from iterative simulation using multiple sequences. Stat Sci. 1992; 7: 457-511.
16. Bowsher WG, Taylor BA, Hughes LE., Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg. 1986; 73: 906-908.
17. Burmeister BH, Smithers BM, Davis S, et al. Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg. 2002; 72: 344-348.
18. Lawton G, Rasque H, Ariyan S., Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma. J Am Coll Surg. 2002; 195: 339-351.
19. Serpell JW, Carne PW, Bailey M., Radical lymph node dissection for melanoma. ANZ J Surg. 2003; 73: 294-299.
20. Urist MM, Maddox WA, Kennedy JE, Balch CM., Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer. 1983; 51: 2152-2156.
21. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003; 10: 676-680.
22. Carlson JW, Kauderer J, Walker JL, et al. A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol Oncol. 2008; 10: 76-82.
23. Werngren-Elgstrom M, Lidman D., Lymphoedema of the lower extremities after surgery and radiotherapy for cancer of the cervix. Scand J Plast Reconstruct Surg Hand Surg. 1994; 28: 289-293.
24. Wolff HA, Overbeck T, Roedel RM, et al. Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. J Cancer Res Clin Oncol. 2009; 135: 961-967.
25. Robinson MH, Spruce L, Eeles R, et al. Limb function following conservation treatment of adult soft tissue sarcoma. Eur J Cancer. 1991; 27: 1567-1574.
26. Brouns E, Donceel P, Stas M., Quality of life and disability after ilio-inguinal lymphadenectomy. Acta Chir Belg. 2008; 108: 685-690.
27. Holmes EC, Moseley HS, Morton DL, Clark W, Robinson D, Urist MM., A rational approach to the surgical management of melanoma. Ann Surg. 1977; 186: 481-490.
28. Ravi R., Morbidity following groin dissection for penile carcinoma. Br J Urol. 1993; 72: 941-945.
29. de, Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ., Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. Eur J Surg Oncol. 2005; 31: 778-783.
30. de, Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ., Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol. 2006; 32: 785-789.
31. Baas PC, Schraffordt Koops H, Hoekstra HJ, van Bruggen JJ, van der Weele LT, Oldhoff J., Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity. Arch Surg. 1992; 127: 281-286.
32. James JH., Lymphoedema following ilio-inguinal lymph node dissection. Scand J Plast Reconstruct Surg. 1982; 16: 167-171.
33. Starritt EC, Joseph D, McKinnon JG, et al. Lymphedema after complete axillary node dissection for melanoma: assessment using a new, objective definition. Ann Surg. 2004; 240: 866-874.
34. Common Toxicity Criteria. Cancer Therapy Evaluation Program, 1999. Available at: Accessed April 30, 1999.
35. Rubin P, Constine LS III, Fajardo LF, Phillips TL, Wasserman TH., EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol. 1995; 35: 9-10.
36. Bergmark K, Avall-Lundqvist E, Dickman PW, et al. Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand. 2002; 81: 443-450.
37. Bilek K, Ebeling K, Leitsmann H, Seidel G., Radical pelvic surgery versus radical surgery plus radiotherapy for stage Ib carcinoma of the cervix uteri. Preliminary results of a prospective randomized clinical study. Archiv fur Geschwulstforschung. 1982; 52: 223-229.
38. Chatani M, Nose T, Masaki N, Inoue T., Adjuvant radiotherapy after radical hysterectomy of the cervical cancer. Prognostic factors and complications. Strahlenther Onkol. 1998; 174: 504-509.
39. Clark PB., Radical cystectomy for carcinoma of the bladder. Br J Urol. 1978; 50: 492-495.
40. Fiorica JV, Roberts WS, Greenberg H, Hoffman MS, LaPolla JP, Cavanagh D., Morbidity and survival patterns in patients after radical hysterectomy and postoperative adjuvant pelvic radiotherapy. Gynecol Oncol. 1990; 36: 343-347.
41. Fujiwara K, Kigawa J, Hasegawa K, et al. Effect of simple omentoplasty and omentopexy in the prevention of complications after pelvic lymphadenectomy. Int J Gynecol Cancer. 2003; 13: 61-66.
42. Greskovich FJ, Zagars GK, Sherman NE, Johnson DE., Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J Urol. 1991; 146: 798-802.
43. Henningsohn L, Wijkstrom H, Dickman PW, et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2002; 62: 215-225.
44. Kavoussi LR, Sosa E, Chandhoke P, et al. Complications of laparoscopic pelvic lymph node dissection. J Urol. 1993; 149: 322-325.
45. Kridelka FJ, Berg DO, Neuman M, et al. Adjuvant small field pelvic radiation for patients with high risk, stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection. A pilot study. Cancer. 1999; 86: 2059-2065.
46. Lieskovsky G, Skinner DG, Weisenburger T., Pelvic lymphadenectomy in the management of carcinoma of the prostate. J Urol. 1980; 124: 635-638.
47. Logmans A, Kruyt RH, de Bruin HG, Cox PH, Pillay M, Trimbos JB., Lymphedema and lymphocysts following lymphadenectomy may be prevented by omentoplasty: a pilot study. Gynecol Oncol. 1999; 75: 323-327; comment 2001;80:107-108.
48. Martimbeau PW, Kjorstad KE, Kolstad P., Stage IB carcinoma of the cervix, the Norwegian Radium Hospital, 1968-1970: results of treatment and major complications. I. Lymphedema. Am J Obstet Gynecol. 1978; 131: 389-394.
49. Orr JW Jr, Holloway RW, Orr PF, Holimon JL., Surgical staging of uterine cancer: an analysis of perioperative morbidity. Gynecol Oncol. 1991; 42: 209-216.
50. Rainwater LM, Zincke H., Radical prostatectomy after radiation therapy for cancer of the prostate: feasibility and prognosis. J Urol. 1988; 140: 1455-1459.
51. Snijders-Keilholz A, Hellebrekers BW, Zwinderman AH, van de Vijver MJ, Trimbos JB., Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984-1996). Radiother Oncol. 1999; 51: 161-167.
52. Tanaka T, Ohki N, Kojima A, et al. Radiotherapy negates the effect of retroperitoneal nonclosure for prevention of lymphedema of the legs following pelvic lymphadenectomy for gynecological malignancies: an analysis from a questionnaire survey. Int J Gynecol Cancer. 2007; 17: 460-464.
53. Uno T, Ito H, Itami J, et al. Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors. Anticancer Res. 2000; 20: 2235-2239.
54. Yeh SA, Wan Leung S, Wang CJ, Chen HC., Postoperative radiotherapy in early stage carcinoma of the uterine cervix: treatment results and prognostic factors. Gynecol Oncol. 1999; 72: 10-15.
55. Padilla J, Sheldon RD, Sitar DM, Newcomer SC., Impact of acute exposure to increased hydrostatic pressure and reduced shear rate on conduit artery endothelial function: a limb-specific response. Am J Physiol Heart Circ Physiol. 2009; 297: H1103-H1108.
56. Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G., Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer. 2001; 92: 1783-1787.
57. Langer S, Guenther JM, Haigh PI, Difronzo LA., Lymphatic mapping improves staging and reduces morbidity in women undergoing total mastectomy for breast carcinoma. Am Surg. 2004; 70: 881-885.
58. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007; 25: 3657-3663.
59. Kerchner K, Fleischer A, Yosipovitch G., Lower extremity lymphedema update: pathophysiology, diagnosis, and treatment guidelines. J Am Acad Dermatol. 2008; 59: 324-331.
60. Finegold DN, Kimak MA, Lawrence EC, et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum Mol Genet. 2001; 10: 1185-1189.
61. Ferrell RE, Finegold DN., Research perspectives in inherited lymphatic disease: an update. Ann N Y Acad Sci. 2008; 1131: 134-139.
62. Rockson SG., Secondary lymphedema: is it a primary disease? Lymphat Res Biol. 2008; 6: 63-64.
63. Ward L., Is BIS ready for prime time as the gold standard measure? J Lymphoedema. 2009; 4: 52-56.
64. Karakousis CP, Heiser MA, Moore RH., Lymphedema after groin dissection. Am J Surg. 1983; 145: 205-208.
65. Papachristou D, Fortner JG., Comparison of lymphedema following incontinuity and discontinuity groin dissection. Ann Surg. 1977; 185: 13-16.
66. Jacobellis U., Modified radical inguinal lymphadenectomy for carcinoma of the penis: technique and results. J Urol. 2003; 169: 1349-1352.
67. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008; 26: 884-889.
68. Moore RG, Robison K, Brown AK, et al. Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial. Gynecol Oncol. 2008; 109: 65-70; comment 2008;111:158; author reply 2008;111:159.
69. Zhang X, Sheng X, Niu J, et al. Sparing of saphenous vein during inguinal lymphadenectomy for vulval malignancies. Gynecol Oncol. 2007; 105: 722-726.
70. Bellati F, Angioli R, Manci N, et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol Oncol. 2005; 96: 227-231.
71. Judson PL, Jonson AL, Paley PJ, et al. A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy. Gynecol Oncol. 2004; 95: 226-230.
72. Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer. 2003; 13: 522-527.
73. de Hullu JA, Ansink AC, Tymstra T, van der Zee AG,. What doctors and patients think about false-negative sentinel lymph nodes in vulvar cancer. J Psychosom Obstet Gynecol. 2001; 22: 199-203.